PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...

Eli Lilly (NYSE:LLY) shares reached a new 52-week low on Thursday as concerns over late-stage trial data for the company’s ...

Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased ...

A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which targets both GLP-1 and amylin receptors to help control blood sugar and ...

Novo Nordisk ( NVO 1.34%) and Regeneron Pharmaceuticals ( REGN -0.27%), two leading drugmakers, have underperformed for most ...

Subcutaneous amycretin phase 1 b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American ...

Amycretin trial showed weight loss of 9.7% to 22% over 36 weeks at varying doses, compared to weight gain with placebo. Common side effects were mild-to-moderate gastrointestinal issues, aligning ...

Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, which target GLP-1 and GIPR receptors. Following the release of the trial results, ...

Amycretin mimics the action of two different hunger-related hormones at once, says Novo Nordisk, the Danish pharma company developing the drug. The drug mimics glucagon, which is the hormone also ...